What's happened
Novo Nordisk has regained momentum with oral Wegovy, outpacing Eli Lilly's Foundayo in the U.S. obesity-drug market. The rivalry includes a divisive court case and signals renewed optimism after a challenging 2025, with analysts watching for a longer-term turnaround.
What's behind the headline?
Critical analysis
- Novo Nordisk has shifted from a defensive stance to offense, leveraging oral Wegovy to defend its lead in a two-horse race with Lilly.
- The court case against Lilly highlights strategic positioning in the U.S. market, where advertising and efficacy comparisons influence perception and demand.
- The dynamic underscores a broader trend: obesity drugs are moving toward deeper U.S. penetration and new delivery formats, which could alter pricing and payer dynamics.
- The next quarters will test whether Wegovy’s early adoption translates into durable growth as Lilly introduces competitors like orforglipron and expands Mounjaro/Zepbound usage beyond diabetes and obesity.
- For readers, expect continued volatility: policy, pricing, and regulatory moves will shape the pace of this market’s evolution.
How we got here
Novo Nordisk faced pricing pressure and four guidance cuts in 2025, prompting a major restructuring and CEO change. In 2026, the company has pushed back with Wegovy’s strong uptake, particularly the oral pill in the U.S., while Lilly’s stronger Zepbound and Mounjaro continue to challenge its position.
Our analysis
The Japan Times: Novo Nordisk gains ground on Wegovy as Lilly counters; CNBC: Novo lifts full-year guidance on Wegovy sales; Independent: Novo aims to outpace Lilly in obesity drug market. Direct quotes feature across sources to illustrate the competitive debate.
Go deeper
- Will Wegovy's performance sustain against Foundayo in the coming quarters?
- How might the Lilly court case influence U.S. advertising rules for obesity drugs?
- What does this mean for patients choosing between Wegovy and Foundayo?
More on these topics
-
United States - Country in North America
The United States of America, commonly known as the United States or America, is a country mostly located in central North America, between Canada and Mexico.
-
Novo Nordisk - Danish pharmaceutical company
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S (wholly owned by the Novo Nordisk Foundation) which holds approximately 28.1% of its shares and a majority (77.1%) of its voting shares. Novo Nordisk manufactures and markets pharmaceutical products and services, specifically diabetes and obesity medications and devices. Novo Nordisk employs more than 48,000 people globally, and markets its products in 168 countries. The corporation was created in 1989, through a merger of two Danish companies, which date back to the 1920s. Novo Nordisk is a full member of the European Federation of Pharmaceutical Industries and Associations (EFPIA). The company was ranked 25th among Fortune's 100 Best Companies to Work For in 2010, and subsequently ranked 72nd in 2014 and 73rd in 2017. In January 2012, Novo Nordisk was named the most sustainable company in the world by the business magazine Corporate Knights, while spin-off company Novozymes was named fourth. It is a leader in the FTSE4Good Index, and the only European company in the top ten. Novo Nordisk is the largest pharmaceutical company...